This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Exploring the current treatment landscape for Hemophilia A & B, including CSL Behring's Hemgenix (etranacogene dezaparvovec-drlb) and Biomarin's potential gene therapy ROCTAVIAN (valoctocogene roxaparvovec)

Ticker(s): BMRN, CSLLY, QURE

Who's the expert?

  • Staff Hematologist, Course Director for Hematology, and Program Director of bone marrow biopsies at a Major U.S. Healthcare center.
  • Currently managing 12 patients with Hemophilia A. 
  • Clinical interests include Coagulation disorders, including hemophilia, von Willebrand's disease, clotting factor deficiencies or inhibitors, thrombophilia, lupus anticoagulant or antiphospholipid syndrome, thrombocytopenia, and hemolytic anemia.

Interview Questions

Have you prescribed Hemgenix at your practice?

Added By: max_admin

How would an approval for ROCTAVIAN alter the current treatment landscape?

Added By: max_admin

How do the treatment landscapes differ for Hemophilia A versus Hemophilia B

Added By: max_admin

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.


*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.